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Tuberculosis (TB) is one of the oldest diseases known to affect 
humanity, and is still a major public health problem. It is 
caused by the bacillus Mycobacterium tuberculosis (MT), iso-
lated in 1882 by Robert Koch. Until the 1950s, X rays were 
used as a cheap method of diagnostic screening together with 
the tuberculin skin sensitivity test. In the diagnosis and treat-
ment of TB, an important role was also played by surgery. The 
late Nineteenth century saw the introduction of the tuberculosis 
sanatorium, which proved to be one of the first useful measures 
against TB. Subsequently, Albert Calmette and Camille Gué-
rin used a non-virulent MT strain to produce a live attenuated 
vaccine. In the 1980s and 1990s, the incidence of tuberculosis 
surged as a major opportunistic infection in people with HIV 
infection and AIDS; for this reason, a combined strategy based 
on improving drug treatment, diagnostic instruments and pre-
vention was needed.
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Summary
Introduction and historical approach
Tuberculosis (TB) is one of the oldest diseases known 
to affect humanity [1]. It is caused by the bacillus My-
cobacterium tuberculosis (MT): the bacilli usually mul-
tiply in the lungs and are spread by air-borne droplets 
from infected persons [2]. The disease reached epidemic 
proportions in Europe and North America during the 
Eighteenth and Nineteenth centuries [3] and today, with 
around 10.4 million new cases each year, almost one 
third of the world’s population are carriers of the TB 
bacillus and at risk of developing active disease. India, 
Indonesia, China, Pakistan and the Philippines account 
for 56% of new tuberculosis cases [4], while the Dem-
ocratic People’s Republic of Korea, Lesotho, Mozam-
bique, the Philippines and South Africa have the high-
est incidence rate, with over 500 new cases per 100,000 
inhabitants [5]. In the past, MT displayed a predilection 
for young people and was called the "thief of youth"; in 
most cases, it proved fatal, with a death proportion in the 
pre-chemotherapy era: roughly 65% at 5 years, especial-
ly when it was associated to malnutrition, overcrowding 
and poor living and working conditions [6]. Over the last 
two centuries, the disease felled an estimated one billion 
people worldwide, and today, despite effective chemo-
therapy, it is estimated to be responsible for 1.7 million 
deaths, including the 380,000 among people with HIV 
infection normally classified under AIDS deaths by ICD 
convention, being the second greatest cause of mortal-
ity among infectious diseases in the world after human 
immunodeficiency virus (HIV) [1, 5]. Villemin was the 
first to prove that human tuberculosis was a contagious 
disease transmitted by an infectious agent, Mycobacte-
rium tuberculosis [7]. This microbe was discovered and 
isolated in 1882 by the famous scientist Robert Koch, 
who was awarded the Nobel Prize for Medicine in 1905. 
After Villemin’s definitive nosographic classification, 
the ravages of tuberculosis spurred many scientists in 
the following decades to seek an effective way of curb-
ing the disease, and different and sometimes conflicting 
public health strategies were implemented [8]. 
Isolation and staining of the Koch bacillus
Robert Koch observed that the alcohol-methylene blue 
staining developed by Karl Weigert in 1875 did not eas-
ily stain in tubercular lesions [9, 10]. He therefore im-
plemented an innovative method of observing tubercular 
lesions by means of methylene-blue and a solidified me-
dium of coagulated bovine serum heated to 40°C [11]. 
Using this staining technique, Koch reported that animal 
tissues and bacteria stained brown, whereas tubercular 
bacteria were easily detected on microscopy, as they ap-
peared bright blue  [12]. This innovation enabled Koch 
to prove that the various manifestations of tuberculosis, 
such as scrofula, pulmonary, extra-pulmonary and me-
ningeal tubercular diseases, had a common cause, and 
also allowed him to reproduce the disease in experimen-
tally inoculated guinea pigs  [6, 11, 13-18].
Inspired by Koch’s work, Paul Ehrlich further modi-
fied the staining protocol and began working on a bet-
ter method of staining, using aniline water, fuschin and 
gentian-violet: the blue background counterstain showed 
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up the bacilli as red spots [18]. In 1882, Franz Ziehl in-
troduced carbol fuschin instead of aniline, and Friedrich 
Neelson substituted sulphuric acid for nitric acid, which 
stained the bacillus a brighter red; this was known as the 
Ziehl-Neelson (ZN) stain or acidalcohol-fast bacillus 
(AAFB), since, once stained, the MT bacillus lipidic wall 
resists decoloring by acid and alcohol; for this reason, this 
technique is also used nowadays in order to isolate the 
MT bacillus [15]. In the following decades, microscopy 
continued to be the gold standard isolation method, and 
enabled a diagnosis to be made in a short time with high 
specificity. Moreover, it was cheap and simple to use [19]. 
In order to improve sensitivity, other methods of concen-
tration, such as centrifugation, N-acetyl cysteine-sodium 
hydroxide, bleach, ammonium sulfate or chitin, were 
tested and used in countries where the disease displayed 
a high prevalence. In addition, the classical ZN staining 
was replaced by Kinvoun staining and immunofluores-
cence [19]. In more recent years, other cold staining meth-
ods were used to diagnose tuberculosis, such as Gabbet’s 
method and a modified two-reagent cold staining method, 
which were less time consuming and easier to perform in 
the field [20]. Currently, the fluorescent stain auramine is 
used to better detect positive smears. In the past, its use 
was limited by the need to replace the light source in fluo-
rescent microscopes every 200-300 hours. Subsequently, 
the innovative use of light-emitting diodes (LED), which 
last for tens of thousands of hours, proved to be a valid 
and more economical alternative to fluorescent micro-
scopes, and today the World Health Organization (WHO) 
recommends replacing conventional ZN microscopy for 
the diagnosis of pulmonary tuberculosis even in resource-
poor countries [21, 22].
X-rays and the tuberculosis skin test:  
two effective diagnostic methods
Wilhelm Konrad von Röntgen was awarded the Nobel 
Prize for his contribution to the control of tuberculosis 
through his studies and his 1895 discovery of X-rays, 
which were used as an effective TB diagnostic tech-
nique. By using a Crooke’s cathode, he succeeded in 
producing a shadow of a metal object on a photograph-
ic plate. This enabled him to visualize internal organs 
and detect TB lesions in the lungs, from Ghon foci to 
apical cavitation. This technique was used as a cheap 
method of diagnostic screening until the 1950s, togeth-
er with the tuberculin skin sensitivity test. Nowadays 
X-rays are still used as a screening tool. In 1890, Koch 
obtained from tubercular bacilli a concentrated fil-
trate of liquid cultures, called "tuberculin" or "Koch’s 
lymph" [23]. He believed it was an effective method of 
curing animals of tuberculosis, and announced his in-
tention to test it in humans. Tuberculin was later nick-
named "la kockine", in French "coquine", which means 
"mischievous" as in "playful", but also as in "causing 
mischief"  [7]. Koch had prepared the substance by 
means of crops in glycerin broth in six weeks, killed 
by heating at 100°C, filtered and evaporated to one 
tenth. Up to 0.25 ml of these crops could be injected 
into humans [24, 25]. It was a clear, brownish liquid, 
which was easy to store. However, it could be used in 
humans only in a very diluted form because it caused 
very violent reactions, such as inflammation at the site 
of inoculation, intense tuberculous reaction, high fever, 
expansion of tubercular lesions, more or less extensive 
necrosis and the onset of nephritis. This liquid was ac-
tive only if injected subcutaneously, not when ingested. 
In healthy individuals, the subcutaneous injection of tu-
berculin did not cause any sort of reaction, while if in-
jected into a subject already affected by the infection, it 
elicited an intense reaction, including fever, chills and 
vomiting, as happened to Koch himself [26, 27]. Tuber-
culin retained a place in the treatment of some forms 
of tuberculosis until the Second World War; later, it 
found application in the diagnosis of tuberculosis: the 
famous "tuberculin reaction" test, which used the same 
principle involved in the diagnosis of other diseases, 
such as glanders (Mallein Est) and brucellosis (bru-
cella test)  [24]. In 1907, a Viennese pediatrician and 
immunologist, Clemens Freiherr von Pirquet (1874-
1929), used cutaneous tuberculin scratch tests, later 
called the Pirquet test, to diagnose in children "latent 
tuberculosis", a term which he himself introduced into 
medicine. The reaction to tuberculin, which he called 
"allergy", unmasked contagion even in individuals who 
showed no sign of the disease or who had overcome the 
clinically manifested disease  [28]. In 1910, a French 
physician, Charles Mantoux (1877-1947), improved 
Pirquet’s method, by using a cannulated needle and 
syringe to inject tuberculin between the layers of the 
skin. This permitted more accurate control of the dose 
of tuberculin used. Today, the gold standard test used 
to diagnose TB is tuberculin purified protein deriva-
tive (PPD). Developed in the 1930s by two American 
biochemists, Florence B. Seibert and Esmond R. Long, 
this is a more sensitive test than tuberculin [6, 28]. In 
1952, Carroll Palmer and Leroy Bates published the 
results of a large study of reactions to one test unit of 
PPD-S in more than 3,000 hospitalized tuberculosis pa-
tients [29]. Fewer than one percent failed to react; skin 
reactions were normally about 15  mm in size. Some 
years later, other studies conducted in hospitalized tu-
berculosis patients and in school children in various 
parts of the world demonstrated that, in countries with 
a high prevalence of tuberculosis, a significant percent-
age of healthy school children displayed skin reactions 
that were similar in size to those seen in tuberculous 
patients [30]. This finding confirmed von Pirquet’s the-
ory of latent tuberculous infections, as did LB Edwards 
and CE Palmer’s experiments, in which nonspecific tu-
berculin reactivity was caused by the cross-reaction to 
the antigen of environmental mycobacteria in guinea 
pigs [31]. Thus, tuberculin skin test studies contributed 
to our understanding of tuberculosis and other non tu-
berculous mycobacterial infections and of the immune 
response to human and animal TB [32].
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The role of surgery in treating 
tuberculosis: pneumothorax
In the diagnosis and treatment of tuberculosis, an impor-
tant role was also played by surgery and other invasive 
techniques. Indeed, some anatomic and physiological con-
ditions originally observed in patients with other diseases 
were successfully exploited to treat tuberculosis. The first 
such case was described in 1696 by Giorgio Baglivi, who 
reported that the clinical TB of a patient who suffered 
pneumothorax as a result of a sword wound improved. 
Later, in 1771, Edmond Claude Bourru, a librarian at the 
Faculté de Médecine in Paris, first suggested the benefit of 
lung collapse. Subsequently, in 1834 in London, FH Ram-
adge reported the first successful therapeutic pneumotho-
rax in one of his patients. In order to cure and prevent the 
spread of TB infection, two surgeons, Edouard Bernard de 
Cérenville and Max Schede, used a new method of unilat-
eral rib resection, called thoracoplasty, between 1885 and 
1890. This enabled them to reduce thoracic cavity volume 
and collapse tuberculous cavities. In 1888, Carlo Forlani-
ni, an Italian physician, undertook a new therapeutic inter-
vention; he created the first artificial intrapleural pneumo-
thorax by collapsing the lung and filling the pleural cavity 
with nitrogen. This technique at first appeared paradoxi-
cal, since spontaneous pneumothorax had, up to then, been 
seen as one of the complications of pulmonary tubercu-
losis. This therapeutic technique was successfully applied 
until the 1970s and was abandoned only after the advent of 
anti mycobacterial drug therapies [33, 34]. Thoracoplasty, 
which had first been introduced by the Swiss surgeon De 
Cérenville, was taken up by two Norwegian physicians, 
L Brauer and PL Fridrich, as a diagnostic technique for 
tuberculosis; its safety profile was very good as it did not 
involve the pleural space, and so minimized the risk of tu-
berculous empyema. Surgical treatments for tuberculosis 
were developed and used until the 1940s. However, they 
were followed by some complications, such as infections, 
fistula and empyema. The efficacy of these interventions 
was reported in various papers. For instance, in 1939 
the Briton Oli Hjaltested published the results of a study 
conducted on 191 patients between 1925 and 1931 [35], 
while another paper described the outcome of 557 patients 
treated with pneumothorax between 1930 and 1939 [36]. 
After the discovery of effective antibiotic therapy, surgical 
treatments were progressively abandoned in favor of safer 
treatment. Neverless, there are some countries (e.g., for-
mer USSR) that kept using surgery abundantly under the 
claim that their cases are more advanced and complicated 
by drug resistance.
Introduction of the tuberculosis 
sanatorium
The late 19th century saw the introduction of one of the 
first useful measures to combat tuberculosis, that is to say, 
improving hygiene conditions. Indeed, fresh air, proper 
nutrition and exercise had been prescribed for phthisis 
throughout history by famous scientists, including Hip-
pocrates and Aretaeus of Cappadocia. In France, the gov-
ernment started to structure the fight against tuberculosis. 
"Selection centers" to identify soldiers with consumption, 
and "health stations", the precursors of "public sanatori-
ums", were created in order to treat tuberculosis suffer-
ers, and above all to provide them with information on 
prevention, before they were sent home. Phthisiotherapy, 
also known as sanatorium treatment, was first proposed 
by a German physician, Hermann Brehmer. The sanato-
rium was a place where patients were treated with fresh 
air, rest, a rich diet, mountain walks and water [6]. In the 
middle of the Nineteenth century, the Italian doctor Bia-
gio Castaldi, who suffered from pulmonary tuberculosis 
himself, published a summary of his clinical observa-
tions in the Journal of Medical Sardinian States [37]. He 
reaffirmed the great efficacy of a healthy lifestyle and a 
high mountain climate in preventing the disease. Indeed, 
he observed that these conditions could boost the body’s 
mechanisms of defense and repair, first arresting the 
progression of the disease and subsequently healing lo-
cal lesions and the general damage produced. At the end 
of the Nineteenth century, tuberculosis was widespread, 
especially among the poorer classes, and sanatoria were 
designed for these categories, too. In these places, peo-
ple could work in order to obtain adequate treatment and 
food. Those who could not afford to stay in sanatoria were 
instructed to remain isolated from other persons living in 
the same house [13]. Treatment in sanatoria was under-
taken in many countries until the Twentieth century, and 
several hospitals had therapeutic open-air wards. In most 
cases, however, only patients with minimal disease bene-
fited; most of those with severe complications died within 
a short time [14].
The prevention of tuberculosis:  
TB vaccines and Bacille Calmette-Guérin 
(BCG) immunization
In the 19th century, vaccination against tuberculosis was 
advocated in Italy by Edoardo Maragliano, followed 
by Giovanni and Gaetano Petragnani Salvioli, and in 
France by Albert Calmette and Camille Guérin. In 1886, 
the Venetian doctor Vittorio Cavagnis made the first pio-
neering experiment, in which killed bacilli were used in 
order to achieve a state of preventive immunity against 
infection. Cavagnis tentatively vaccinated some animals 
by means of the inoculation of tuberculous sputum treat-
ed with carbolic acid solution  [38]. In 1891, Jacques-
Joseph Grancher and P-Ledox Lebard experimented 
with immunization based on the principle of Pasteur’s 
inoculations of crops of progressively increasing viru-
lence. They started by inoculating avian tuberculosis 
bacilli cultures subjected to different aging processes, 
but had to admit that these cultures, when inoculated 
into guinea pigs, did not confer immunity against mam-
malian tuberculosis [39]. In 1895, Edoardo Maragliano 
claimed that it would always be preferable to use a vac-
cine with the bacillus of human type that contains the an-
tigenic complex counterpart. He believed that the bodies 
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of desiccated bacilli were able to induce the production 
of specifically bactericidal substances in the organism 
into which they were inoculated [40]. On the basis of his 
research, he proposed a dual solution for the treatment 
of tuberculosis: an active specific therapy based on the 
administration of a tuberculin prepared by himself and 
a passive serum therapy, based on the administration of 
serum obtained from vaccinated animals. In 1901, Fran-
cisque Crotte proposed an "electrical" remedy for TB. A 
year later, von Behring, together with Romer and Rup-
pel, publicized a method called "jennerization" of cat-
tle. They used a culture of tubercular bacilli of human 
origin, which had been maintained for over six years in 
the laboratory and then dried under vacuum, the viru-
lence of which had proved extremely low in the guinea 
pig. Increasing amounts of the culture were injected in-
travenously into calves aged about six months on two 
occasions, initially with a 6-week interval, and then a 
3-month interval, between injections. Another line of 
research was also moving forward; this was aimed at 
immunizing humans by administering live bacteria ob-
tained from patients. Indeed, in France, Cavagnis had 
been injecting progressively higher doses of a mixture of 
phenolized water and saliva from tuberculosis patients. 
In 1905, two French bacteriologists and pasteurians, Al-
bert Calmette and Camille Guérin, began their search 
for an anti-tuberculosis vaccine at the Pasteur Institute 
in Lille. On 8 January 1908, a strain of tuberculosis ba-
cillus isolated by Nocard was cultured on pieces of po-
tato cooked in 5% glycerinated beef bile; after 230 suc-
cessive cultures, Calmette and Guérin observed in 1920 
that these bacilli were no longer able to infect guinea 
pigs or rabbits, even at high doses [41]. The strain was 
called Billié Calmette-Guérin, from which they were 
able to produce a non-virulent strain which they formu-
lated into a live attenuated vaccine, later called Bacille 
Calmette-Guérin or BCG [42]. In 1921, BCG was first 
administered to humans by two French physicians, Ben-
jamin Weille-Hallé and Raymond Turpin, at the Charité 
Hospital in Paris. The vaccine was administered orally 
to an infant born to a mother who had died of tubercu-
losis shortly after giving birth; the child survived and 
did not contract the disease. The vaccine soon became 
popular throughout Europe and, over the next seven 
years, more than 100,000 children were immunized. 
Subsequently, the oral formulation of BCG was replaced 
by a subcutaneous formulation according to the method 
of Loeffler and Matsda (1913), in which the bacterial 
bodies killed by heat were first dried and then heated 
to 70°C for 15 days. The subcutaneous vaccine proved 
more active, but soon they noticed that it often resulted 
in considerable damage, causing the skin to ulcerate and 
even liquefy; they therefore adopted intradermal admin-
istration as the method of choice. A vaccine developed 
by Koch and named "Tauruman", made by using living 
human tuberculosis bacilli with attenuated virulence, 
was marketed in the early years of the 20th century. In 
1930, 250 children immunized with a BCG vaccine in 
Lübeck in Germany were accidentally contaminated by 
virulent tubercular bacilli; seventy-three subjects died 
of tuberculosis in the first year and a further 135 were 
hospitalized [43]. The Second World War was followed 
by a resurgence of tuberculosis throughout Europe and 
Asia, and in 1948 UNICEF undertook a tuberculosis 
control program of tuberculin testing and BCG vaccina-
tion in children. Routine vaccination was discontinued 
in the 1970s and in the following decades, but is still im-
plemented in many countries with a high prevalence of 
tuberculosis, in order to prevent childhood tuberculous 
meningitis and miliary disease, and in healthcare, mili-
tary personnel and other people at high risk of exposure 
to tuberculosis.
New prophylactic and therapeutic vaccines
Since the beginning of the 21st century, new prophylactic 
vaccines have been tested in order to better control the 
pulmonary form of TB. One strategy could be to boost 
the current BCG vaccine with new subunit vaccines. 
Moreover, more effective recombinant BCG or attenu-
ated live vaccines have been tested for use in primary 
immunization  [44]. In the past century, the BCG vac-
cine was used in various countries and protected many 
children and adults from TB. However, its effectiveness 
against pulmonary TB was variable. For this reason, 
various formulations of new-generation TB vaccines are 
currently being tested and are in various phases of clini-
cal trials, the aim being to achieve lasting immuniza-
tion [45]. In 2016, 13 candidate vaccines were tested in 
clinical trials, including candidates for the prevention of 
TB infection and candidates for the prevention of TB dis-
ease in people with Latent TB Infection [5]. These can-
didate vaccines are intended not only to provide stronger 
immunological responses against MT, but also to elicit 
long-lasting responses, which will require stimulation 
of memory T- and B-cell responses  [46]. Currently, 8 
of the 13 vaccines in clinical development are subunit 
vaccines; 6 of these contain or express either Ag85A or 
Ag85B proteins. A major challenge to TB vaccine de-
velopment is the lack of diversity in both the antigens 
included in TB vaccines, and the immune responses elic-
ited by TB vaccine candidates. Both will need to be ex-
panded to maximize the potential for developing a suc-
cessful candidate by 2025. [47] Live attenuated vaccines 
interfere with phagosome biology and host intracellular 
pathways, including apoptosis and autophagy. In recent 
studies, mucosal vaccination was found to be superior 
to parenteral vaccination, and this innovative route of 
administration is currently under study  [48]. In recent 
years, a new hypothesis of cure was introduced by a new 
formulation of TB vaccine. The effectiveness of this vac-
cine is based on the theory that mycobacterial antigens 
can enhance bacterial killing. A phase II study of Myco-
bacterium indicus pranii (Mw) vaccine administered via 
the aereosol route is being examined in guinea pig and 
mouse models. RUTI is a non-live polyantigenic vaccine 
that may be used as a prophylactic vaccine together with 
short intensive antibiotic therapy; it is currently being 
tested in a phase II trial [5, 49].
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The discovery of streptomycin  
and other anti-tuberculosis drugs
During the 21st century, antibacterial chemotherapy was 
developed, with the discovery of numerous active mol-
ecules against the Koch bacillus, such as thiosemicarba-
zone, acid or para-PAS and hydrazide isonicotinic acid. In 
the 1930s, tuberculosis was shown to be resistant to sul-
phonamides and, in the 1940s, to penicillin. The Ukrain-
ian microbiologist Selman Waksman, who was awarded 
the Nobel prize in 1952, coined the term "antibiotic". He 
first isolated actinomycin in 1940 and streptothricin in 
1942, both of which would later be used effectively in 
TB therapy, but which were too toxic in their first formu-
lations. Other anti-tuberculosis chemotherapeutic agents 
were developed in the following years, such as isoniazid, 
rifampicin, ethambutol and pyrazinamide, and more re-
cently, viomycin and ciprofloxacin, used to treat drug-
resistant infections. The strategy of early diagnosis and 
targeted therapy with chemotherapy is now considered to 
have the absolute best cost/benefit ratio. 
Tuberculosis and AIDS: the challenge  
of multidrug-resistant tuberculosis
In the 1980s and 1990s, the incidence of tuberculosis 
surged as a major opportunistic infection in people with 
HIV infection and AIDS, as a result of their immune sys-
tem impairment. Today, TB is still a significant cause of 
both illness and death in developed countries, especially 
among immunosuppressed individuals; indeed, subjects 
with HIV have a higher TB-related mortality rate than the 
general population  [50]. Moreover, the risk of develop-
ing tuberculosis is estimated to be between twelve-twen-
ty times greater in people living with HIV than in those 
without HIV infection [5]. In 2015, 15% of tuberculosis 
patients worldwide (1.2 million people) had HIV co-
infection, and in parts of sub-Saharan Africa, the figure 
was as high as 50-80%. Tuberculosis is the leading cause 
of death in people with HIV infection and AIDS; one 
in three AIDS sufferers dies from tuberculosis  [51, 52]. 
While the incidence of HIV-related tuberculosis has de-
clined in developed countries, owing to effective anti-TB 
and anti-HIV treatment, it remains high in many develop-
ing countries.[53] In a study published by Karo B et al. in 
2017, HIV-infected patients who contracted TB showed 
redued CD4+ cell counts; in these patients, it is important 
to start adjunctive TB preventive therapy [54].
New strategies for reducing HIV-related TB infections 
could be: the use of cheaper, more effective and less 
toxic drugs; early diagnosis based on PCR technologies 
in the case of MDR-TB infection, as this may be cured 
with bedaquiline and delamanid, which are effective 
against both sensitive and resistant strains; and, in the 
meantime, improving the use of ART in HIV patients. 
In the near future, an integrated approach will have to be 
developed, including new and more sensitive diagnostic 
tests, together with rapid and effective therapy [55].
Towards the elimination of tuberculosis: 
tuberculosis control strategy
In 1993, the WHO declared TB a global emergency, and in 
1995 defined a tuberculosis control strategy – the directly 
observed treatment, short-course strategy, also known 
as DOTS  –  the most important health breakthrough of 
the decade in terms of the number of lives that could be 
saved [56, 57]. Thanks to the DOTS strategy, the global 
incidence of tuberculosis has fallen by 1.5% every year 
since 2000, and from 2000 to 2015 the mortality rate de-
clined by about 22%  [58]. Nevertheless, morbidity and 
mortality rates worldwide are still high, especially in de-
veloping countries; indeed, 60% of TB deaths occur in 
six countries: India, Indonesia, China, Nigeria, Pakistan 
and South Africa [50]. In 1998, the complete MT genome 
sequence was published, which raised expectations of de-
veloping better therapies for TB and vaccines to prevent 
it [59]. In recent decades, however, multidrug-resistant tu-
berculosis (MDR-TB) has emerged and is now present in 
most countries. Patients infected with strains resistant to 
isoniazide and rifampicin are incurable by means of first 
line therapy. The response to tuberculosis treatment may 
be affected by multiple factors associated with the host-
pathogen interaction, including genetic factors and the 
nutritional status of the host [60]. Drug resistance surveil-
lance data indicate that, in 2015, approximately 480,000 
people contracted MDR-TB worldwide and 97,000 MDR-
TB patients were started on treatment. Surveillance of TB 
drug resistance over the last two decades has informed 
and guided the response to the MDR-TB epidemic, and 
recent innovations in molecular diagnostics have prompt-
ed a definitive shift to routine surveillance [61]. In 2016, 
an MDR tuberculosis treatment regimen of less than a 
year’s duration was recommended on a global scale. Five 
priority actions, from prevention to cure, are required. The 
issues of health system barriers, diagnostic and treatment 
challenges and inadequate funding for care and research 
must be urgently addressed [62]. Developing new drugs, 
improving diagnostics and introducing new TB vaccines 
are critical components of a strategy to combat TB in gen-
eral, and drug-resistant TB in particular [63]. In TB en-
demic areas, children are particularly vulnerable to drug-
resistant TB; for this reason, a major goal is to improve 
access to currently available vaccines and treatment, in or-
der to curb the continuing spread of drug-resistant TB, es-
pecially in younger people. According to the WHO Stop 
TB program, daily treatment with isoniazid for subjects 
at high risk of active tuberculosis is an effective preven-
tive measure at both the individual and collective levels. 
Other preventive measures are recommended in national 
programs and in the guidelines of the WHO stop TB pro-
gram, the aim being to provide universal access to TB 
diagnosis and treatmen [64]. The discovery of Mycobac-
terium tuberculosis-specific immunodominant antigens 
has led to the development of interferon gamma-release 
assays, which have been shown to have high sensitivity 
and specificity for TB disease [65]. Despite considerable 
progress, however, these techniques should be improved 
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in order to extend their use to low-resource countries and 
to cases of paucibacillary TB [66, 67].
Conclusions
In Western countries, tuberculosis has greatly diminished 
in recent decades, and in these areas vaccination remains 
a selective remedy for vulnerable groups. In the last dec-
ade, however, tuberculosis morbidity has increased, ris-
ing from three million to ten million new cases annually; 
this rise is associated with the growth of co-infection 
with AIDS, which occurs especially in developing coun-
tries, particularly in Africa. In addition, the problem of 
under-notification of cases of TB must be remembered, 
which will hamper future efforts to reduce the incidence 
of the disease. In highly endemic countries, the WHO 
continues to maintain mass vaccination to prevent child-
hood tuberculosis, though it is acknowledged that this 
cannot break the “chain” of disease, which is sustained 
by adults with full-blown pulmonary forms. Since 2012, 
the WHO has implemented the TB end strategy, which 
is based on the development of new tools to better de-
tect, prevent and treat tuberculosis. In the coming years, 
the challenge will be to succeed in translating innovative 
discoveries into public health targets and socioeconomic 
interventions in local tuberculosis control programs.
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